Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 13 symbols : Abbv save search
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Published: 2022-04-13 (Crawled : 23:00) - prnewswire.com
GNMSF | News | $289.67 3.83% 5.3K
|
Health Technology
|
| O: -0.14%
H: 3.21%
C: 1.5%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.69%
H: 3.81%
C: 2.83%
GMAB | News | $28.56 -1.42% 500K
|
Health Technology
|
| O: -0.86%
H: 2.28%
C: -0.08%
cd20 duobody topline trial phase 1
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Published: 2022-04-13 (Crawled : 22:00) - globenewswire.com
GNMSF | News | $289.67 3.83% 5.3K
|
Health Technology
|
| O: -0.14%
H: 3.21%
C: 1.5%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.69%
H: 3.81%
C: 2.83%
GMAB | News | $28.56 -1.42% 500K
|
Health Technology
|
| O: -0.86%
H: 2.28%
C: -0.08%
cd20 duobody topline trial phase 1
Flagship Caps Busy Week with Addition of AbbVie's Michael Severino
Published: 2022-04-13 (Crawled : 20:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval
Published: 2022-04-13 (Crawled : 16:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
botox fda approval
Antiviral Drugs Market Size To Reach USD 50.02 BN In 2030 Due to Development Of New, Improved, And More Advanced Formulations, Such As Repurposed Drugs And Drug Combination Therapies, Says Reports and Data
Published: 2022-04-13 (Crawled : 15:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 1.76%
H: 0.35%
C: 0.35%
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -0.83%
NVS | News | $97.295 2.29% 0.0% 3.7M
|
Health Technology
|
| O: 0.12%
H: 0.44%
C: 0.17%
JNJ | News | $149.48 0.24% 6.8M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
GSK | News | $41.245 1.61% 2M
|
Health Technology
|
| O: -0.24%
H: 0.45%
C: 0.39%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
GILD | $67.01 0.09% 3.5M
|
Health Technology
|
| O: -0.02%
H: 0.8%
C: 0.71%
drug antiviral repurposed market
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 380K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.